KPMG partner Sanjay Singh to lead BDA Partners in India
Sanjay Singh, a partner at KPMG India deal advisory and head of its life sciences practice, has left his role at the Big Four accounting and advisory firm to join BDA Partners – a global, Asia-focused investment banking advisory firm.
Singh takes over as managing director and head of BDA India, while also taking the joint lead on the firm’s Asian Healthcare team. He will work out of BDA’s Mumbai office, alongside fellow managing directors Kumar Mahtani and Manoj Balwani – who respectively head up the firm’s consumer & industrial and technology practices.
“I’ve enjoyed working with Sanjay in the past, and I’m excited to welcome him onboard,” said Mahtani. The pair worked together at KPMG – where Mahtani was an associate director for M&A between 2006 and 2011, and where Singh has spent the last 13 plus years of his professional career.
Singh was most recently partner and head of life sciences at KPMG, providing transaction support for myriad corporate clients across pharma, health and chemicals. Big names on his portfolio include Baxter, Isagro, Johnson & Johnson, Nihon Nohyaku, Roquette and SMT.
His work was informed by first-hand experience in life sciences, notably as manager at Dr. Reddy’s Laboratories and deputy general manager at Glenmark Pharma. He now brings this expertise to BDA – where the global team is gearing up for a boom in cross-border M&A activity.
“India is a priority for BDA. We anticipate continuing growth in M&A and private equity activity,” said global managing partner and head of healthcare at BDA Andrew Huntley. The firm’s India office – built up by Mahtani and Balwani – has already amassed a notable client base including Actis, EQT, Flex, Larsen & Toubro and Partners Group.
“With Sanjay joining, we have a senior team of three MDs in Mumbai, offering coverage across our core sectors for corporates and financial sponsors. BDA’s clients, especially in the Health sector, will benefit from Sanjay’s experience,” added Huntley.
Singh chimed in with his own satisfaction with the move. “BDA is enjoying a good growth trajectory in India, providing a strong value proposition to both financial sponsors and strategic clients, and offering connectivity to the West and across Asia.”
“I’m pleased to join BDA in this exciting phase and look forward to adding value for BDA’s blue-chip clients.” Singh will likely have a packed agenda: healthcare consumption in India is booming, pushing many in the sector to experiment with new technologies. Deals and inorganic expansion will likely underpin this transformation.
